GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » PensionAndRetirementBenefit

LAVA Therapeutics NV (LAVA Therapeutics NV) PensionAndRetirementBenefit : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV PensionAndRetirementBenefit?

LAVA Therapeutics NV's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was $0.00 Mil.


LAVA Therapeutics NV PensionAndRetirementBenefit Historical Data

The historical data trend for LAVA Therapeutics NV's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV PensionAndRetirementBenefit Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - - - -

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LAVA Therapeutics NV PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.